openPR Logo
Press release

Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare

11-12-2021 07:47 PM CET | Health & Medicine

Press release from: SMi Group

Ai in drug discovery, Artificial intelligence, AI, Retrosynthetic analysis, machine learning, Drug Discovery, drug development

Ai in drug discovery, Artificial intelligence, AI, Retrosynthetic analysis, machine learning, Drug Discovery, drug development

SMi Group reports: the 3rd Annual AI in Drug Discovery is set to return to London in March 2022 with a key focus on the opportunities of machine learning and AI in drug development

SMi Group is delighted to announce the 3rd Annual AI in Drug Discovery conference, taking place on the 14th and 15th March 2022 in London, UK. The 2022 Conference theme is on exploring the opportunities of machine learning.

Chair for the conference is industry expert Darren Green, Director of Molecular Design, GSK.

New to 2022 is the AI in Drug Discovery post conference workshops on: “From Drug Discovery to Healthcare, an AI insight” and “Deciphering AI Based Drug Discovery” taking place on 16th March 2022.

Interested parties can register for the conference and workshops at http://ww.ai-indrugdiscovery.com/PR1 and take advantage of the early bird offer to save £400 which expires 30th November 2021.

The conference will also bring together expert speakers which include:

• Andrew Pattison, Digital Health and Innovation Team, World Health Organisation
• Gregory Vladimer, VP Translation Research, Translation Biology, Exscientia
• Kim Branson, SVP Global Head of Artificial Intelligence and Machine Learning, GSK
• Christian Tyrchan, Associate Director Computational Chemistry, AstraZeneca
• Friedrich Rippmann, Computational Chemistry & Biology, Merck
• Mathew Divine, Senior Data Scientist, Boehringer Ingelheim
• Alexander Hillisch, Pharmaceuticals, R&D, Computational Molecular Design, Bayer AG
• Peter Henstock, Machine Learning & AI Technical Lead, Merck

By attending the conference, attendees will have the chance to:

• Discover the main topics of research within industry, with talks on decision making, target selection and closing the loop
• Engage with regulators about the guidance within machine learning and AI in Drug Discovery
• Learn about the new breakthroughs within clinical trials and the treatment of disease
• Explore the latest technologies in deep learning from leaders within the pharmaceutical industry
• Discuss the impact of big data and how it applies to AI drug discovery within Pharma

Attend the SMi's 3rd annual AI in Drug Discovery conference and explore the latest industry updates in the selection of targets using AI, decision making within drug discovery and closing the loop on AI in drug discovery.

Leading presentations from leaders within the field who will be giving their insights into the latest industry advances and answering the big questions within AI in Drug Discovery.

View the agenda and speaker line–up at http://ww.ai-indrugdiscovery.com/PR1

Sponsored by Optibrium
For sponsorship enquiries contact Alia Malick, Director on +44 (0)20 7827 6168 or e-mail amalick@smi-online.co.uk

For media enquiries or a press pass contact Simi Sapal, Head of Marketing on +44 (0) 20 7827 6000 or email ssapal@smi-online.co.uk

SMi’s 3rd Annual AI in Drug Discovery 2022
15 – 16 March 2022
London, UK
#SMiAIDrugDis
http://ww.ai-indrugdiscovery.com/PR1

--- END ---

45 Curlew Street
London, UK
SE1 2ND

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare here

News-ID: 2460884 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Drug

Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights: * Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 * Global and Regional Antibody Drug Conjugate Market Insight * Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023 * Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight * Insight On Antibody Drug Conjugates In Clinical Trials: > 550
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase